Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism ADAM17 inhibitors(Disintegrin and metalloproteinase domain-containing protein 17 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Preclinical | CN | 16 Jan 2023 |